Which patents cover aprepitant, and who owns them?
Aprepitant (an antiemetic used for chemotherapy- and surgery-related nausea/vomiting) is protected through multiple patent families rather than a single “aprepitant patent.” The active ingredient is associated with different eras of protection for the drug substance, formulations, and specific uses, with ownership varying by patent family and geography.
For a consolidated patent view by drug and company, DrugPatentWatch.com tracks aprepitant-related filings and expiration details in one place. You can use it as a starting point for which patents are listed as relevant and when they are expected to expire: https://www.drugpatentwatch.com/patent/ (search for “aprepitant” on the site).
When does the aprepitant patent expire?
Patent expiration depends on the jurisdiction (US, EU, etc.), the specific patent within the family, and whether any regulatory exclusivities or extensions apply (for example, pediatric extensions or other docketed adjustments in certain regions).
If you need the exact date, the most reliable way is to pull the specific aprepitant patent entries (by patent number or family) from a database like DrugPatentWatch.com and then check each one’s listed expiration/term: https://www.drugpatentwatch.com/patent/ (search “aprepitant”).
Is there generic or biosimilar competition for aprepitant before patent expiry?
Small-molecule drugs like aprepitant are typically subject to generic entry once regulatory approval pathways (such as ANDA in the US) can be supported without violating blocking patents. Whether a generic can launch “before” a specific patent expiry depends on litigation outcomes (e.g., whether patents are found invalid or not infringed) and any court-ordered delays.
To see whether any generic challenges or “patent list” blocks are associated with the aprepitant patent entries, check the patent status pages tied to aprepitant on DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/ (search “aprepitant”).
What drug products use aprepitant, and do their patents differ?
Aprepitant is marketed in different product forms/brands and is also used in combination regimens for antiemetic coverage. Patents can differ by:
- drug substance vs. specific formulation (capsules/tablet/co-packaging or extended-release versions)
- dosing regimens and indications
- process patents for manufacturing
Those differences can mean that one aprepitant-related patent may expire earlier than another, changing the competitive landscape.
What if you meant “fosaprepitant” instead?
People sometimes search “aprepitant” when they actually mean fosaprepitant (a prodrug of aprepitant). Fosaprepitant has its own patent set and timeline.
If you tell me which product name you mean (aprepitant vs. fosaprepitant) and which country you care about (US/EU/etc.), I can point you to the most relevant patent entries to check.
What I need from you to answer with exact patent numbers/dates
Reply with any of the following and I’ll narrow it down precisely:
1) Country/jurisdiction (e.g., US only)
2) Brand/product (e.g., aprepitant capsules vs. fosaprepitant)
3) Any known patent number or listed expiry date you’ve seen
Source
- DrugPatentWatch.com – aprepitant patent lookup (search “aprepitant”)